Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 13/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12826290 | 0.86 | ABL1 (0.37) | ABL1PTGS1PTGS2DGAT1ALOX5AP | |
| SCHEMBL12825941 | 0.80 | BRPF1 (0.31) | — | |
| SCHEMBL1460334 | 0.78 | ACLY (0.35) | ACLY | |
| SCHEMBL12826642 | 0.78 | ALOX5AP (0.36) | ABL1PTGS1PTGS2ALOX5APORAI1 | |
| SCHEMBL1463839 | 0.76 | ORAI1 (0.35) | ABL1ALOX5APORAI1ACLY | |
| SCHEMBL15959129 | 0.69 | CYP2A6 (0.45) | PTGS1PTGS2DGAT1PIK3CA | |
| SCHEMBL1463766 | 0.69 | SCN9A (0.40) | PTGS1PTGS2 | |
| SCHEMBL1460249 | 0.66 | BRD9 (0.38) | ACLY | |
| SCHEMBL12825992 | 0.66 | — | — | |
| SCHEMBL16475095 | 0.63 | NNMT (0.47) | ABL1ORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ORAI1, RYR2, CACNA1E | ABL1 2048/4885PTGS1 656/4885PTGS2 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.